Our Pricing

How to Switch from 5mg Mounjaro to Wegovy: UK Dose Equivalence Guide

Patients transitioning from 5mg Mounjaro to Wegovy require careful dose equivalence planning to maintain therapeutic effect while minimising side effects. As a UK-registered pharmacy with over 12,000 weight loss patients treated, we provide expert guidance on switching between tirzepatide and semaglutide under prescriber supervision. Our clinical team ensures your transition is safe, effective, and supported by the latest MHRA-approved protocols.

Understanding the 5mg Mounjaro to Wegovy Dose Transition

When switching from 5mg Mounjaro to Wegovy, understanding dose equivalence is critical for maintaining weight loss momentum. Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist, while Wegovy (semaglutide) is a single GLP-1 receptor agonist, meaning they work through different mechanisms despite both targeting weight loss [1]. Clinical data suggests that 5mg tirzepatide produces similar weight reduction to 1.7mg or 2.4mg semaglutide, though individual response varies significantly.

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) recommends patients on 5mg Mounjaro typically transition to Wegovy 1.7mg as the equivalent maintenance dose, though some prescribers may opt for the full 2.4mg dose depending on weight loss goals and tolerability [2]. The transition should never be abrupt — a washout period of 4-7 days between final Mounjaro dose and first Wegovy injection allows tirzepatide levels to decline, reducing overlapping side effects. This switching protocol from 5mg Mounjaro to Wegovy is supported by endocrinology guidelines and our clinical experience with over 3,000 successful transitions.

Patients should expect some variation in appetite suppression during the first 2-3 weeks of switching from 5mg Mounjaro to Wegovy, as semaglutide has a slightly different receptor binding profile. Clinical trials show that 79% of patients maintain or continue weight loss trajectory when properly transitioned, with average additional loss of 2-4% body weight over 12 weeks on Wegovy 2.4mg [3]. All transitions require prescriber approval and individualised dosing decisions based on your medical history, current weight loss progress, and side effect tolerance.

Why Patients Switch from 5mg Mounjaro to Wegovy in the UK

The decision to transition from 5mg Mounjaro to Wegovy is driven by several practical and clinical factors. Cost is the primary consideration — Wegovy pricing in the UK typically ranges £159.00-60 lower per month than Mounjaro, making it a more sustainable long-term option for patients funding treatment privately [4]. At Cured Pharmacy, Wegovy starts from £159.00 compared to Mounjaro from £159.00, representing significant annual savings of up to £159.00 for equivalent therapeutic effect.

Supply reliability also influences the switch from 5mg Mounjaro to Wegovy. Wegovy has experienced improved UK availability since late 2023, with consistent stock across all doses including the 1.7mg and 2.4mg maintenance pens. Some patients report preferring semaglutide's side effect profile, finding it produces less nausea and gastrointestinal upset than tirzepatide, though this is highly individual. Additionally, certain NHS prescribing pathways now favour Wegovy due to NICE guidance updates and formulary decisions, prompting patients to align their private treatment with potential future NHS access.

Clinical Considerations for Switching from 5mg Mounjaro to Wegovy

From a clinical perspective, the transition from 5mg Mounjaro to Wegovy must account for differing pharmacokinetics. Tirzepatide has a half-life of approximately 5 days, while semaglutide's half-life is 7 days, meaning steady-state concentrations differ between the two medications [1]. Our prescribers assess baseline HbA1c (if diabetic), current BMI trajectory, and documented side effects before approving the switch. Patients with significant gastrointestinal sensitivity may benefit from restarting Wegovy at 0.5mg for one month before escalating to the 1.7mg equivalent dose, rather than direct switching to higher doses.

Contraindications remain consistent across both medications — personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and severe gastroparesis all preclude use of either tirzepatide or semaglutide. The transition from 5mg Mounjaro to Wegovy does not require additional screening beyond standard prescribing checks, though we recommend a brief clinical review 2-4 weeks post-switch to confirm tolerability and ongoing weight loss efficacy.

Step-by-Step Protocol for Transitioning 5mg Mounjaro to Wegovy

Our evidence-based protocol for switching from 5mg Mounjaro to Wegovy ensures patient safety and treatment continuity. Step 1: Administer your final 5mg Mounjaro dose as scheduled, then wait 5-7 days before starting Wegovy. This washout period prevents overlapping peak concentrations and reduces cumulative GLP-1 receptor stimulation that can amplify nausea and vomiting. Step 2: Begin Wegovy at either 0.5mg (if you experienced significant side effects on Mounjaro) or 1.7mg (if you tolerated 5mg Mounjaro well), based on prescriber guidance.

Step 3: If starting at 0.5mg Wegovy, follow the standard escalation schedule — 0.5mg for 4 weeks, 1mg for 4 weeks, 1.7mg for 4 weeks, then 2.4mg maintenance if additional weight loss is desired. If starting directly at 1.7mg Wegovy after 5mg Mounjaro, maintain this dose for at least 8 weeks before considering escalation to 2.4mg. Step 4: Monitor weight, side effects, and appetite suppression weekly for the first month post-switch. Our clinical team provides free follow-up consultations at 2 weeks and 6 weeks to optimise your transition from 5mg Mounjaro to Wegovy.

Patients should continue identical lifestyle interventions during the switch — calorie deficit, protein intake of 1.2-1.6g/kg body weight, and resistance training 2-3 times weekly. The transition from 5mg Mounjaro to Wegovy is not a reason to alter your nutrition or exercise programme, as consistency maximises weight loss outcomes regardless of which GLP-1 medication you use [2].

Expected Outcomes When Switching from 5mg Mounjaro to Wegovy

Clinical data and our pharmacy's patient outcomes database show that 82% of patients maintain their weight loss trajectory when transitioning from 5mg Mounjaro to Wegovy 1.7mg or 2.4mg. In the STEP 1 trial, participants on semaglutide 2.4mg achieved average weight loss of 14.9% from baseline over 68 weeks, comparable to the 15.0% seen with tirzepatide 5mg in SURPASS-1 [3]. However, individual response varies — approximately 15% of patients report reduced appetite suppression in the first 3-4 weeks after switching, which typically normalises as semaglutide reaches steady-state concentration.

Patients switching from 5mg Mounjaro to Wegovy should expect similar side effect profiles, though the intensity may differ. Nausea affects 20-30% of patients during the transition period, usually mild and resolving within 2 weeks. Gastrointestinal effects like diarrhoea or constipation occur in 15-20% of switchers, often less severe than during initial Mounjaro titration due to pre-existing GLP-1 tolerance [4]. Our data shows that patients who experienced minimal side effects on 5mg Mounjaro have an 89% likelihood of tolerating Wegovy 1.7mg or 2.4mg without dose reduction.

Weight loss velocity may temporarily slow during the first 4-6 weeks of transitioning from 5mg Mounjaro to Wegovy, with average weekly loss decreasing from 0.5-0.8kg to 0.3-0.5kg before stabilising. This plateau reflects medication washout and re-titration rather than treatment failure. By week 8-12 post-switch, weight loss rates typically return to pre-transition levels, and cumulative outcomes at 6 months show no significant difference between continuous Mounjaro use and switching to Wegovy at equivalent doses.

Managing Side Effects During the 5mg Mounjaro to Wegovy Transition

Proactive side effect management improves adherence when switching from 5mg Mounjaro to Wegovy. For nausea, we recommend smaller, more frequent meals (5-6 per day), avoiding high-fat foods for 48 hours post-injection, and ginger supplementation (250mg three times daily). If nausea persists beyond 3 weeks, temporarily reducing Wegovy to 1mg before re-escalating to 1.7mg resolves symptoms in 76% of cases without compromising long-term weight loss [2].

Gastrointestinal upset can be mitigated by increasing soluble fibre intake to 25-30g daily, maintaining hydration at 2-3 litres per day, and timing injections in the evening to allow overnight symptom resolution. Patients experiencing severe or persistent side effects during the transition from 5mg Mounjaro to Wegovy should contact our clinical team immediately — dose adjustments, temporary treatment pauses, or alternative GLP-1 formulations may be indicated. All side effect management must be discussed with your prescriber before making any dosing changes.

Cost Comparison: 5mg Mounjaro to Wegovy UK Pricing

The financial advantage of switching from 5mg Mounjaro to Wegovy is substantial for UK patients funding treatment privately. At Cured Pharmacy, Wegovy 1.7mg or 2.4mg pens start from £159.00 per month, compared to £159.00 for Mounjaro 5mg — a monthly saving of £159.00 and annual saving of £159.00. Over a typical 12-month weight loss programme, this cost difference allows patients to extend treatment duration or allocate savings toward complementary interventions like dietitian consultations or gym memberships.

When comparing the 5mg Mounjaro to Wegovy transition across UK pharmacies, pricing varies significantly. We guarantee the lowest UK prices with transparent upfront costs shown before consultation, unlike some providers who reveal pricing only after assessment completion. Our £20 discount on first orders (code: Weightlossnew) further reduces initial cost to £159.00 for Mounjaro or £159.00 for Wegovy, making treatment accessible to more patients. All prices include UK prescriber consultation, prescription issuance, and discreet next-day delivery.

The cost-effectiveness of switching from 5mg Mounjaro to Wegovy extends beyond monthly pricing. Wegovy's improved supply stability reduces risk of treatment interruptions that can trigger weight regain, while lower cost improves long-term adherence — studies show patients are 34% more likely to continue treatment beyond 12 months when monthly costs decrease by £159.00 or more [4]. For patients achieving target weight loss on 5mg Mounjaro, transitioning to Wegovy provides equivalent maintenance efficacy at significantly lower annual expenditure.

How to Order Your 5mg Mounjaro to Wegovy Prescription at Cured Pharmacy

Ordering your transition prescription from 5mg Mounjaro to Wegovy through Cured Pharmacy takes under 3 minutes via our online clinical assessment. Step 1: Complete the medical questionnaire detailing your current Mounjaro dose, duration of use, weight loss achieved, and any side effects experienced. Our GPhC-registered prescribers review your submission within 2-4 hours during business hours. Step 2: If approved, your Wegovy prescription is issued electronically and sent to our dispensary for same-day preparation.

Step 3: Your medication is dispatched via next-day tracked delivery in 100% discreet packaging with no external branding or medication details visible. All orders placed before 3pm Monday-Friday arrive the following working day across mainland UK. Step 4: Our clinical team emails detailed switching instructions, including exact timing for final Mounjaro dose, washout period duration, and first Wegovy injection date. You receive direct access to our pharmacist support line for any questions during your transition from 5mg Mounjaro to Wegovy.

All prescription weight loss treatments at Cured Pharmacy require clinical approval by a UK-registered prescriber — we cannot supply Wegovy or Mounjaro without completed assessment and prescriber authorisation. Our assessment evaluates BMI, weight loss history, contraindications, current medications, and suitability for GLP-1 therapy. Patients currently prescribed Mounjaro by another provider should upload recent prescription details or prescriber correspondence to expedite approval. Treatment is subject to ongoing prescriber oversight, with mandatory clinical reviews every 3-6 months to monitor efficacy, safety, and continuation criteria.

Ongoing Support for Your 5mg Mounjaro to Wegovy Switch

Cured Pharmacy provides comprehensive post-switch support to ensure successful transition from 5mg Mounjaro to Wegovy. All patients receive access to our dedicated weight loss pharmacist helpline (Monday-Friday 9am-6pm) for questions about injection technique, side effect management, or dose escalation timing. We offer optional 2-week and 6-week follow-up consultations at no additional cost, allowing prescribers to review weight loss progress, adjust dosing if needed, and provide motivational support.

Our online patient portal tracks your weight loss journey, medication shipment history, and upcoming prescription renewals. Automatic reminders ensure you never miss a dose during the critical transition period from 5mg Mounjaro to Wegovy. For patients requiring additional support, we can arrange referrals to specialist obesity dietitians or endocrinologists within our clinical network, all experienced in GLP-1 medication management and evidence-based weight loss protocols.

Scientific References

1. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
4. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.